000169158 001__ 169158
000169158 005__ 20241125122424.0
000169158 0247_ $$2doi$$a10.1158/1535-7163.MCT-20-0394
000169158 0247_ $$2pmid$$apmid:34108262
000169158 0247_ $$2ISSN$$a1535-7163
000169158 0247_ $$2ISSN$$a1538-8514
000169158 037__ $$aDKFZ-2021-01292
000169158 041__ $$aEnglish
000169158 082__ $$a570
000169158 1001_ $$aVassal, Gilles$$b0
000169158 245__ $$aInternational consensus on minimum preclinical testing requirements for the development of innovative therapies for children and adolescents with cancer.
000169158 260__ $$aPhiladelphia, Pa.$$bAACR$$c2021
000169158 3367_ $$2DRIVER$$aarticle
000169158 3367_ $$2DataCite$$aOutput Types/Journal article
000169158 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1634566671_21234
000169158 3367_ $$2BibTeX$$aARTICLE
000169158 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000169158 3367_ $$00$$2EndNote$$aJournal Article
000169158 500__ $$a2021 Aug;20(8):1462-1468
000169158 520__ $$aCancer remains the leading cause of disease-related death in children. For the many children who experience relapses of their malignant solid tumors, usually after very intensive first-line therapy, curative treatment options are scarce. Preclinical drug testing to identify promising treatment elements that match the molecular make-up of the tumor is hampered by the fact that 1) molecular genetic data on pediatric solid tumors from relapsed patients and thus our understanding of tumor evolution and therapy resistance are very limited to date and 2) for many of the high-risk entities, no appropriate and molecularly well characterized patient-derived models and/or genetic mouse models are currently available. However, recent regulatory changes enacted by the EMA (class waiver changes) and the maturation of the RACE for Children act with the FDA, will require a significant increase in preclinical pediatric cancer research and clinical development must occur. We detail the outcome of a pediatric cancer international multistakeholder meeting whose output aims at defining an international consensus on minimum preclinical testing requirements for the development of innovative therapies for children and adolescents with cancer. Recommendations based on the experience of the NCI funded PPTP/C (www.ncipptc.org) and the EU funded ITCC-P4 public private partnership (www.itccp4.eu) are provided for the use of cell-based and mouse models for pediatric solid malignancies, as well as guidance on the scope and content of preclinical proof-of-concept data packages to inform clinical development dependent on clinical urgency. These recommendations can serve as a minimal guidance necessary to jumpstart preclinical pediatric research globally.
000169158 536__ $$0G:(DE-HGF)POF4-312$$a312 - Funktionelle und strukturelle Genomforschung (POF4-312)$$cPOF4-312$$fPOF IV$$x0
000169158 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
000169158 7001_ $$aHoughton, Peter J$$b1
000169158 7001_ $$0P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aPfister, Stefan M$$b2$$udkfz
000169158 7001_ $$00000-0001-9880-9876$$aSmith, Malcolm A$$b3
000169158 7001_ $$aCaron, Huib N$$b4
000169158 7001_ $$aLi, Xiao-Nan$$b5
000169158 7001_ $$aShields, David J$$b6
000169158 7001_ $$0P:(DE-He78)143af26de9d57bf624771616318aaf7c$$aWitt, Olaf$$b7
000169158 7001_ $$aMolenaar, Jan J$$b8
000169158 7001_ $$aColombetti, Sara$$b9
000169158 7001_ $$00000-0003-1984-7343$$aSchuler, Julia$$b10
000169158 7001_ $$aStancato, Lou F$$b11
000169158 773__ $$0PERI:(DE-600)2062135-8$$a10.1158/1535-7163.MCT-20-0394$$gp. molcanther.0394.2020 -$$n8$$p1462-1468$$tMolecular cancer therapeutics$$v20$$x1538-8514$$y2021
000169158 8564_ $$uhttps://inrepo02.dkfz.de/record/169158/files/1462-1.pdf
000169158 8564_ $$uhttps://inrepo02.dkfz.de/record/169158/files/1462-1.pdf?subformat=pdfa$$xpdfa
000169158 909CO $$ooai:inrepo02.dkfz.de:169158$$pVDB
000169158 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000169158 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)143af26de9d57bf624771616318aaf7c$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000169158 9131_ $$0G:(DE-HGF)POF4-312$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunktionelle und strukturelle Genomforschung$$x0
000169158 9130_ $$0G:(DE-HGF)POF3-312$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunctional and structural genomics$$x0
000169158 9141_ $$y2021
000169158 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2021-01-30
000169158 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2021-01-30
000169158 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2021-01-30
000169158 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2021-01-30
000169158 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-30
000169158 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2021-01-30
000169158 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-01-30
000169158 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-30
000169158 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2021-01-30
000169158 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bMOL CANCER THER : 2019$$d2021-01-30
000169158 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bMOL CANCER THER : 2019$$d2021-01-30
000169158 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x0
000169158 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x1
000169158 9201_ $$0I:(DE-He78)B310-20160331$$kB310$$lKKE Pädiatrische Onkologie$$x2
000169158 980__ $$ajournal
000169158 980__ $$aVDB
000169158 980__ $$aI:(DE-He78)B062-20160331
000169158 980__ $$aI:(DE-He78)HD01-20160331
000169158 980__ $$aI:(DE-He78)B310-20160331
000169158 980__ $$aUNRESTRICTED